Cascadian Therapeutics Inc. (NASDAQ:CASC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Friday.

According to Zacks, “Cascadian Therapeutics, Inc. is a biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer. The company’s product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor which is in preclinical trial stage. Cascadian Therapeutics, Inc., formerly known as Oncothyreon Inc., is headquartered in Seattle, Washington. “

A number of other equities research analysts have also commented on CASC. Cowen and Company reiterated a “buy” rating on shares of Cascadian Therapeutics in a report on Monday, October 10th. Jefferies Group restated a “buy” rating and issued a $3.00 price objective on shares of Cascadian Therapeutics in a report on Tuesday, November 8th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Cascadian Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $3.00.

Shares of Cascadian Therapeutics (NASDAQ:CASC) traded down 1.79% on Friday, hitting $1.10. 182,747 shares of the stock were exchanged. The company’s market cap is $148.84 million. Cascadian Therapeutics has a 12 month low of $0.82 and a 12 month high of $3.75. The company has a 50-day moving average price of $1.24 and a 200 day moving average price of $1.16.

Cascadian Therapeutics (NASDAQ:CASC) last posted its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.08) by $0.01. Equities analysts forecast that Cascadian Therapeutics will post $5.02 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. ProShare Advisors LLC raised its position in shares of Cascadian Therapeutics by 20.3% in the third quarter. ProShare Advisors LLC now owns 85,070 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 14,378 shares during the last quarter. KCG Holdings Inc. increased its stake in shares of Cascadian Therapeutics by 204.6% in the third quarter. KCG Holdings Inc. now owns 137,775 shares of the biopharmaceutical company’s stock valued at $226,000 after buying an additional 92,549 shares during the period. Northern Trust Corp increased its stake in shares of Cascadian Therapeutics by 23.3% in the third quarter. Northern Trust Corp now owns 162,455 shares of the biopharmaceutical company’s stock valued at $267,000 after buying an additional 30,744 shares during the period. Susquehanna International Group LLP increased its stake in shares of Cascadian Therapeutics by 944.4% in the third quarter. Susquehanna International Group LLP now owns 250,788 shares of the biopharmaceutical company’s stock valued at $411,000 after buying an additional 280,488 shares during the period. Finally, BlackRock Institutional Trust Company N.A. increased its stake in shares of Cascadian Therapeutics by 1.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,849,475 shares of the biopharmaceutical company’s stock valued at $3,033,000 after buying an additional 23,406 shares during the period. Institutional investors own 66.46% of the company’s stock.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

5 Day Chart for NASDAQ:CASC

Receive News & Stock Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related stocks with our FREE daily email newsletter.